Abstract 3742: P7170: A potent and oral phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) inhibitor with anti-tumor and anti-angiogenic activity

@inproceedings{Agarwal2012Abstract3P,
  title={Abstract 3742: P7170: A potent and oral phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) inhibitor with anti-tumor and anti-angiogenic activity},
  author={Veena R. Agarwal and Asavari Gajanan Joshi and Magesh Venkataraman and Nikesh K Desai and Dimple R Bhatia and Sarika Chaudhari and Julie L. Bose and Lakshmi Sireesha Kolla and Vijaykumar B. Deore and Nilambari Yewalkar and Sudhesh Kumar and Rajiv S Sharma and Anagha A. Damre and Avinash More and Parkash Singh Gill and Suveena Sharma},
  year={2012}
}
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL The PI3K/mTOR pathway plays an important role in regulating cancer cell proliferation, growth, survival and metabolism. Activation of the PI3K/mTOR pathway by multiple mechanisms is one of the most frequently observed defects in human malignancies. The objective of these studies was to identify a small molecule that has anti-angiogenic activity in addition to PI3K and mTOR activity. P7170, a novel small molecule… CONTINUE READING